Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 21, 2019
Pharmacy Choice - Pharmaceutical News - New Tracers Improve Diagnosis of Cancer and May Be Useful for Treatment - March 21, 2019

Pharmacy News Article

 3/12/19 - New Tracers Improve Diagnosis of Cancer and May Be Useful for Treatment

RESTON, Virginia, March 11 The Society of Nuclear Medicine and Molecular Imaging issued the following news release:

Researchers have identified two new nuclear medicine tracers that make it easier to diagnose and potentially treat cancer. A proof-of-concept investigation, published in the March issue of The Journal of Nuclear Medicine, reports that 68Ga-FAPI positron emission tomography/computed tomography (PET/CT) provides high-contrast images with quality equal to or better than that of the standard 18F-FDG imaging. Further, no diet changes or fasting are needed before beginning imaging with 68Ga-FAPI, and image acquisition times are substantially shorter than with 18F-FDG PET/CT.

"Having an additional diagnostic tool opens up a new door for cancer patients," said Uwe Haberkorn, MD, professor of nuclear medicine at the University Hospital of Heidelberg and the German Cancer Research Center in Heidelberg, Germany. "For those who are facing unmet diagnostic challengesunclear tumor segmentation for radiation therapy, suspicion of false-negative findings, or selection of last-line experimental treatment68Ga-FAPI may help to provide answers."

In processes involving remodeling of tissue (e.g., wound healing), cells called fibroblasts are activated by several factors, including TGFb, leading to the expression of the fibroblast activation protein (FAP). This protein is produced in abnormally large amounts in cancer-associated fibroblasts (CAFs), which promote tumor growth, migration and progression. 68Ga-FAPI is a new class of radiopharmaceutical that can precisely target CAF activity to aid physicians in diagnosis of cancer. As CAFs are present in more than 90 percent of epithelial carcinomasincluding, for example, breast, lung, colon, pancreatic, and head and neck cancersthey are an attractive target for both diagnostic imaging and therapy.

The 50 patients in this analysis were referred by oncologists who were facing unmet diagnostic challenges that could not be solved sufficiently with standard diagnostic means. All patients tolerated the examination well, and no patients reported any symptoms. The favorable characteristics of the new tracers include fast kinetics that seem appropriate for imaging patients even less than 1 h after injection; low background uptake in liver, oral mucosa, and brain; and independence from blood sugar.

Patients benefited from needing no diet changes or preparation for the PET/CT imaging. "A shorter waiting time and shorter scan time can increase patient comfort, which can be especially important for sick patients," Haberkorn stated. "The possibility of early imagingfor example, after only 10 minutes instead of an hourcould also play a part in simplifying clinical workflow."

Since CAFs are genetically more stable than cancer cells, they are less likely to develop resistance to therapy. Also, as the FAPI tracers contain the universal DOTA-chelator, a theranostic approach seems feasible.

"FAPI tracers are a promising avenue for cancer treatment," Haberkorn noted. "What's more, in the future FAPI imaging may also be used to assess and manage cardiac diseases or fibrotic diseases of the lung, liver and kidneys."

The authors of "68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers" include Frederik L. Giesel, Clemens Kratochwil, Thomas Lindner, Manfred M. Marschalek, Anastasia Loktev, Paul Flechsig, Annette Altmann and Walter Mier, Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; Wencke Lehnert, ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft m.b.H, Dresden, Germany; Jurgen Debus, Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany, and Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany; Dirk Jager, Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg, Germany; and Uwe Haberkorn, Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany, Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany, and Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany.



© 2019 Targeted News Service

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Mar 21: HIV Medications: Newer Drugs, Newer Guidelines
Last Chance
Mar 22: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Mar 24: A Look Inside the Top 200 Drugs
Mar 25: Medication Use During Pregnancy & Lactation
Mar 26: Nutrigenomics - Nutritional Influences on the Genome
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415